Baseline symptom score and flow rate can predict failure of medical treatment of lower urinary tract symptoms

prospective 12-year follow-up study

Said Fadel Mishriki*, Omar Aboumarzouk, John T. Graham, Thomas B. Lam, Bhaskar K. Somani

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)
4 Downloads (Pure)

Abstract

OBJECTIVE To assess predictors of failure of medical treatment of lower urinary tract symptoms (LUTS) and evaluate long-term outcome.

METHODS Between January 1993 and September 1994, 178 men referred with LUTS were prospectively recruited. Assessments included maximum urine flow (Qmax), postvoiding residuals (PVR), transrectal ultrasound (TRUS) prostate volumes, American Urological Association symptom score, and validated quality of life (QOL) and bother scores. Treatment failure was defined as need for transurethral resection of the prostate (TURP). Data were collected at baseline, with final follow-up at 12 years. Univariate and multivariate analyses used Kaplan-Meier and the Cox proportional hazards regression model, respectively, to assess covariates on risk of failure and independent variable prognostic values.

RESULTS Median follow-up was 7.9 years (range, 0-12 years). The mean QOL baseline score of 7.1 improved to 3.6 at 6 years and to 3.3 at 12 years (P15 vs 13; hazard ratio, 2.37; 95% confidence interval, 1.29-4.35; P=.005). At 12 years, AUA, QOL, and bother scores statistically improved compared with baseline (13 vs 8, 10 vs 6, and 5 vs 2, respectively). Limitations included attrition bias from nonresponders.

CONCLUSION The beneficial effect of medical treatment persisted for up to 12 years. Treatment is more likely to fail within the first 3 years in patients with low baseline Qmax and high bother scores. UROLOGY 81: 390-395, 2013. (C) 2013 Elsevier Inc.

Original languageEnglish
Pages (from-to)390-395
Number of pages6
JournalUrology
Volume81
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Lower Urinary Tract Symptoms
Treatment Failure
Quality of Life
Transurethral Resection of Prostate
Proportional Hazards Models
Prostate
Multivariate Analysis
Urine
Confidence Intervals
Therapeutics

Keywords

  • management
  • placebo
  • quality-of-life
  • therapy
  • finasteride
  • men
  • surgery
  • benign prostatic hyperplasia
  • clinical progression

Cite this

Baseline symptom score and flow rate can predict failure of medical treatment of lower urinary tract symptoms : prospective 12-year follow-up study. / Mishriki, Said Fadel; Aboumarzouk, Omar; Graham, John T.; Lam, Thomas B.; Somani, Bhaskar K.

In: Urology, Vol. 81, No. 2, 02.2013, p. 390-395.

Research output: Contribution to journalArticle

@article{d7cc5c4ff7fc4a978533fb80c716b152,
title = "Baseline symptom score and flow rate can predict failure of medical treatment of lower urinary tract symptoms: prospective 12-year follow-up study",
abstract = "OBJECTIVE To assess predictors of failure of medical treatment of lower urinary tract symptoms (LUTS) and evaluate long-term outcome.METHODS Between January 1993 and September 1994, 178 men referred with LUTS were prospectively recruited. Assessments included maximum urine flow (Qmax), postvoiding residuals (PVR), transrectal ultrasound (TRUS) prostate volumes, American Urological Association symptom score, and validated quality of life (QOL) and bother scores. Treatment failure was defined as need for transurethral resection of the prostate (TURP). Data were collected at baseline, with final follow-up at 12 years. Univariate and multivariate analyses used Kaplan-Meier and the Cox proportional hazards regression model, respectively, to assess covariates on risk of failure and independent variable prognostic values.RESULTS Median follow-up was 7.9 years (range, 0-12 years). The mean QOL baseline score of 7.1 improved to 3.6 at 6 years and to 3.3 at 12 years (P15 vs 13; hazard ratio, 2.37; 95{\%} confidence interval, 1.29-4.35; P=.005). At 12 years, AUA, QOL, and bother scores statistically improved compared with baseline (13 vs 8, 10 vs 6, and 5 vs 2, respectively). Limitations included attrition bias from nonresponders.CONCLUSION The beneficial effect of medical treatment persisted for up to 12 years. Treatment is more likely to fail within the first 3 years in patients with low baseline Qmax and high bother scores. UROLOGY 81: 390-395, 2013. (C) 2013 Elsevier Inc.",
keywords = "management, placebo, quality-of-life, therapy, finasteride, men, surgery, benign prostatic hyperplasia, clinical progression",
author = "Mishriki, {Said Fadel} and Omar Aboumarzouk and Graham, {John T.} and Lam, {Thomas B.} and Somani, {Bhaskar K.}",
year = "2013",
month = "2",
doi = "10.1016/j.urology.2012.08.104",
language = "English",
volume = "81",
pages = "390--395",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Baseline symptom score and flow rate can predict failure of medical treatment of lower urinary tract symptoms

T2 - prospective 12-year follow-up study

AU - Mishriki, Said Fadel

AU - Aboumarzouk, Omar

AU - Graham, John T.

AU - Lam, Thomas B.

AU - Somani, Bhaskar K.

PY - 2013/2

Y1 - 2013/2

N2 - OBJECTIVE To assess predictors of failure of medical treatment of lower urinary tract symptoms (LUTS) and evaluate long-term outcome.METHODS Between January 1993 and September 1994, 178 men referred with LUTS were prospectively recruited. Assessments included maximum urine flow (Qmax), postvoiding residuals (PVR), transrectal ultrasound (TRUS) prostate volumes, American Urological Association symptom score, and validated quality of life (QOL) and bother scores. Treatment failure was defined as need for transurethral resection of the prostate (TURP). Data were collected at baseline, with final follow-up at 12 years. Univariate and multivariate analyses used Kaplan-Meier and the Cox proportional hazards regression model, respectively, to assess covariates on risk of failure and independent variable prognostic values.RESULTS Median follow-up was 7.9 years (range, 0-12 years). The mean QOL baseline score of 7.1 improved to 3.6 at 6 years and to 3.3 at 12 years (P15 vs 13; hazard ratio, 2.37; 95% confidence interval, 1.29-4.35; P=.005). At 12 years, AUA, QOL, and bother scores statistically improved compared with baseline (13 vs 8, 10 vs 6, and 5 vs 2, respectively). Limitations included attrition bias from nonresponders.CONCLUSION The beneficial effect of medical treatment persisted for up to 12 years. Treatment is more likely to fail within the first 3 years in patients with low baseline Qmax and high bother scores. UROLOGY 81: 390-395, 2013. (C) 2013 Elsevier Inc.

AB - OBJECTIVE To assess predictors of failure of medical treatment of lower urinary tract symptoms (LUTS) and evaluate long-term outcome.METHODS Between January 1993 and September 1994, 178 men referred with LUTS were prospectively recruited. Assessments included maximum urine flow (Qmax), postvoiding residuals (PVR), transrectal ultrasound (TRUS) prostate volumes, American Urological Association symptom score, and validated quality of life (QOL) and bother scores. Treatment failure was defined as need for transurethral resection of the prostate (TURP). Data were collected at baseline, with final follow-up at 12 years. Univariate and multivariate analyses used Kaplan-Meier and the Cox proportional hazards regression model, respectively, to assess covariates on risk of failure and independent variable prognostic values.RESULTS Median follow-up was 7.9 years (range, 0-12 years). The mean QOL baseline score of 7.1 improved to 3.6 at 6 years and to 3.3 at 12 years (P15 vs 13; hazard ratio, 2.37; 95% confidence interval, 1.29-4.35; P=.005). At 12 years, AUA, QOL, and bother scores statistically improved compared with baseline (13 vs 8, 10 vs 6, and 5 vs 2, respectively). Limitations included attrition bias from nonresponders.CONCLUSION The beneficial effect of medical treatment persisted for up to 12 years. Treatment is more likely to fail within the first 3 years in patients with low baseline Qmax and high bother scores. UROLOGY 81: 390-395, 2013. (C) 2013 Elsevier Inc.

KW - management

KW - placebo

KW - quality-of-life

KW - therapy

KW - finasteride

KW - men

KW - surgery

KW - benign prostatic hyperplasia

KW - clinical progression

U2 - 10.1016/j.urology.2012.08.104

DO - 10.1016/j.urology.2012.08.104

M3 - Article

VL - 81

SP - 390

EP - 395

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -